InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc.

NTLA Clue Score53
United States Fiscal year ends December CIK 0001652130 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

21
Insider
Date
Role
Action
Shares
Price
Amount
John M Leonard
2 Nov 2026
President and CEO
Sold on a plan
9,000
$11.99
$107.91K
Michael P Dube
2 Oct 2026
VP, Chief Accounting Officer
Sell
1,864
$12.43
$23.17K
John M Leonard
21 Aug 2026
President and CEO
Sold on a plan
2,785
$13.00
$36.21K
John M Leonard
20 Aug 2026
President and CEO
Sold on a plan
19,890
$12.60
$250.61K
Edward J Dulac III
22 Jul 2026
EVP, Chief Financial Officer
Sell
8,111
$11.25
$91.25K
Edward J Dulac III
2 Jul 2026
EVP, Chief Financial Officer
Sold on a plan
4,677
$18.00
$84.19K
Michael P Dube
1 Jul 2026
VP, Chief Accounting Officer
Sell
2,641
$16.78
$44.32K
Eliana Clark
2 Mar 2026
EVP, Chief Technical Officer
Sell
607
$13.78
$8.36K
James Basta
2 Mar 2026
EVP, General Counsel
Sell
1,211
$13.78
$16.69K
Michael P Dube
5 Jan 2026
VP, Chief Accounting Officer
Sell
2,989
$9.21
$27.53K
Edward J Dulac III
5 Jan 2026
EVP, Chief Financial Officer
Sell
6,379
$9.21
$58.75K
Eliana Clark
5 Jan 2026
EVP, Chief Technical Officer
Sell
9,515
$9.21
$87.63K
David Lebwohl
5 Jan 2026
EVP, Chief Medical Officer
Sell
11,903
$9.21
$109.63K
Fred E Cohen
5 Jan 2026
Director
Buy
150,000
$9.35
$1.40M
James Basta
5 Jan 2026
EVP, General Counsel
Sell
10,397
$9.21
$95.76K
Birgit C Schultes
5 Jan 2026
EVP, Chief Scientific Officer
Sell
8,508
$9.21
$78.36K
John M Leonard
5 Jan 2026
President and CEO
Sell
34,146
$9.21
$314.48K
John M Leonard
12 Dec 2025
President and CEO
Exercised, kept
8,557
$6.83
$58.44K
John M Leonard
11 Dec 2025
President and CEO
Sold after exercise
5,355
$9.59
$51.35K
John M Leonard
11 Dec 2025
President and CEO
Sold after exercise
32,832
$9.47
$310.92K
John M Leonard
11 Dec 2025
President and CEO
Sold after exercise
49,959
$9.49
$474.11K

What was left out

Form 4 filings counted 30
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 3
Sales at will 12
Transactions with no price 0
Shares from compensation/vesting 660,244
History held since 9 May 2016